ABCL - +40% upside with 1:3 RRSet-up nicely after a squeeze for a breakout and a mean reversion to the fibonacci retracement areas.
My target is 0.50 which is $4.24
However, based on analyst ratings the stock could do 400% in the next 12 months.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.60 USD
−146.40 M USD
38.02 M USD
221.93 M
About AbCellera Biologics Inc.
Sector
Industry
CEO
Carl Lars G. Hansen
Website
Headquarters
Vancouver
Founded
2012
FIGI
BBG00LLW2MF2
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.
AbCellera: $15 | a Gem under the radar should be the next crispr or illumina ... it supplies stuff to MODERNA
it could be the secret sauce in pre diagnotics or preventing diseases before they become serious
currently winding down and allocation of shares to serious players and strong hands with conviction in the Ai Tech Cum Biologics
$ABCL - bull flag in the making?A potential bull flag formation in the making for $ABCL. Volume drying up in the flag part of the channel. Would love to see this breakout above $6.
$ABCL get ready for liftoff NASDAQ:ABCL could blow through the light volume gap and return back to the high 6s, low 7s. With AI hype coming back, this might a good time to add to or start a position.
Three soldiers I remember reading somewhere about chart patterns...this is one of them. 3 rising volume spikes indicating a shift in momentum. ABCL is forecast for major growth...I have taken a position here. Would have been great to grab the bottom if you had the confidence!
3 stocks to buy nowABCL, TGNA and BOXL are showing great entries for long term investments that may provide more than 300% return. Interest rate cuts may accelerate the process.
$ABCL a favorite long term but risk ahead$ABCL a favorite long term but risk ahead if markets falter as revenue from Covid treatment stops coming in
ABCL - Cup & Handle Breakout TradeAbcellera Biologics is a biotech stock setting up in a textbook cup with handle pattern.
The stock has growing institutional sponsorship as shown in the chart from MarketSmith on the chart. It also has a relative strength ranking of 97/100.
Shares formed a cup with a 37% depth and have since drift
ABCL - Tight bullish flasNice secondary entry to add to your position.
After breaking out of the previous flag, price consolidated again for almost a week on decling volume.
Enter the stock if it moves over the high from the previous day.
Stoploss can be set at the low of the previous day (tight stop loss) or underneath t
ABCL Possible Stage 2?I'm a novice learning The Man's ways. My crayon drawing on this chart appears to be a close to a Stage 2 breakout. I think. Since ABCL is a yungun' I substituted the 150 for the 50.
Anyone else have an opinion?
XBI looks like a current leading sector.
I still feel its early but I just do what
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ABCL is 2.85 USD — it has increased by 5.17% in the past 24 hours. Watch AbCellera Biologics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange AbCellera Biologics Inc. stocks are traded under the ticker ABCL.
ABCL stock has fallen by −5.94% compared to the previous week, the month change is a 5.95% rise, over the last year AbCellera Biologics Inc. has showed a −48.46% decrease.
We've gathered analysts' opinions on AbCellera Biologics Inc. future price: according to them, ABCL price has a max estimate of 28.00 USD and a min estimate of 5.00 USD. Watch ABCL chart and read a more detailed AbCellera Biologics Inc. stock forecast: see what analysts think of AbCellera Biologics Inc. and suggest that you do with its stocks.
ABCL reached its all-time high on Dec 11, 2020 with the price of 71.91 USD, and its all-time low was 2.34 USD and was reached on Sep 10, 2024. View more price dynamics on ABCL chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ABCL stock is 7.39% volatile and has beta coefficient of 0.60. Track AbCellera Biologics Inc. stock price on the chart and check out the list of the most volatile stocks — is AbCellera Biologics Inc. there?
Today AbCellera Biologics Inc. has the market capitalization of 841.79 M, it has decreased by −4.12% over the last week.
Yes, you can track AbCellera Biologics Inc. financials in yearly and quarterly reports right on TradingView.
AbCellera Biologics Inc. is going to release the next earnings report on Feb 25, 2025. Keep track of upcoming events with our Earnings Calendar.
ABCL earnings for the last quarter are −0.17 USD per share, whereas the estimation was −0.12 USD resulting in a −36.61% surprise. The estimated earnings for the next quarter are −0.13 USD per share. See more details about AbCellera Biologics Inc. earnings.
AbCellera Biologics Inc. revenue for the last quarter amounts to 6.51 M USD, despite the estimated figure of 7.68 M USD. In the next quarter, revenue is expected to reach 7.58 M USD.
ABCL net income for the last quarter is −51.11 M USD, while the quarter before that showed −36.93 M USD of net income which accounts for −38.39% change. Track more AbCellera Biologics Inc. financial stats to get the full picture.
No, ABCL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has 586.00 employees. See our rating of the largest employees — is AbCellera Biologics Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AbCellera Biologics Inc. EBITDA is −215.86 M USD, and current EBITDA margin is −542.57%. See more stats in AbCellera Biologics Inc. financial statements.
Like other stocks, ABCL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AbCellera Biologics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AbCellera Biologics Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AbCellera Biologics Inc. stock shows the sell signal. See more of AbCellera Biologics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.